Skip to main content

Featured Section: Medical Bioinformatics

The Medical Bioinformatics section aims to aid the development and maturation of the field by providing a platform for the translation of datasets into useful clinical applications. The increase in computing capabilities and availability of different data from advanced technologies will allow researchers to build System Biology models of various diseases in order to efficiently develop new therapeutic interventions and reduce the current prohibitively large costs of drug discovery.

Read the latest articles in the Medical Bioinformatics section

Featured research: Spatial transcriptomics atlas reveals the crosstalk between cancer-associated fibroblasts and tumor microenvironment components in colorectal cancer

The tumor-promoting role of tumor microenvironment (TME) in colorectal cancer has been widely investigated in cancer biology. Cancer-associated fibroblasts (CAFs), as the main stromal component in TME, play an important role in promoting tumor progression and metastasis. Some studies have identified different types of CAFs at the single-cell level according to unique gene signatures or functions. However, the types and functions of CAFs varies in different studies or tumor types, suggesting that the functional roles of CAFs in TME is complicated and yet has not been clearly explained.

In this article, Peng and colleagues explored the corsstalk between CAFs and microenvironment in the pathogenesis of colorectal cancer in order to provide basis for precision therapy. Two types of CAFs were identified using integrated data and researchers explored the functional significance of TME.

Featured review: Emerging role of human microbiome in cancer development and response to therapy

According to the involvement of microbiota in modulating physiological processes, any alteration in its composition and diversity has been linked to a variety of pathologies, including cancer. In this bidirectional relationship, colonization with various bacterial species is correlated with a reduced or elevated risk of certain cancers. Notably, the gut microflora could potentially play a direct or indirect role in tumor initiation and progression by inducing chronic inflammation and producing toxins and metabolites. Therefore, identifying the bacterial species involved and their mechanism of action could be beneficial in preventing the onset of tumors or controlling their advancement. Likewise, the microbial community affects anti-cancer approaches’ therapeutic potential and adverse effects.

In this review, Sadrekarimi et al summarize the evidence revealing the microbiota's involvement in cancer and its mechanism, and also delineated how microbiota could predict colon carcinoma development or response to current treatments to improve clinical outcomes.


Journal of Translational Medicine has launched In Review, a new option that provides authors with on-demand information on the status of their manuscript, enables them to share their work with funders and their research community, and allows their colleagues to comment and collaborate - all whilst their manuscript is under review.

Read More

Meet the Editors

Get to know the Editors behind Journal of Translational Medicine! 

Journal News

Please note that Journal of Translational Medicine is no longer considering submissions of study protocols. 

Editor Spotlight

Section: Translational Metagenomics 

Selvasankar Murugesan, Ph.D., is the Senior Research fellow from the microbiome and biomarkers discovery laboratory at Sidra Medicine, Qatar. He focuses on human microbiome-based biomarker discovery to apply in precision medicine. He is an active member of the Mexican Microbiology association (AMM). In addition, he is an Associate Editor for the Journal of Translational Medicine. He holds a Ph.D. in Pharmacology from the Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV), Mexico, where he studied the role of the gut microbiome in childhood obesity.

View the previous 'Editor Spotlights' here

Our companion journal

Translational Medicine Communications. the companion journal to Journal of Translational Medicine, is an interdisciplinary forum for all scientifically valid research from across translational medicine. 

The journal aims to improve transparency and reproducibility within translational medicine and considers research papers regardless of outcome or significance of findings.

Explore Translational Medicine Communications

Introducing new sections to Journal of Translational Medicine!


Led by Section Editor Mary Salvatore, the Fibrosis section aims to gather current high-quality research to better understand the process of normal tissue repair as well as the pathogenetic mechanisms responsible for the onset and progression of tissue fibrosis that leads to organ dysfunction and failure. 

Fibrosis is the common denominator in a variety of chronic diseases including idiopathic pulmonary fibrosis, liver cirrhosis, and ulcerative colitis, among others. These fibrotic diseases affect a vast number of people across the world significantly impacting the quality of their life and increasing health care costs. The Fibrosis section will consider high-quality research articles from basic science to clinical trials.

Cellular Metabolism Therapy

Led by Section Editor Salvatore Nesci, this new section aims to promote the translation of basic research emerging from biochemistry, molecular medicine, physiology and biotechnology into cell metabolism in order to be exploited in clinical applications. 

Cellular Metabolism Therapy will consider research that covers any aspect of translational metabolic research, including (but not limited to): genetic disorders and epigenetic diseases; metabolic derangements causing neurodegeneration; immunometabolism; stroke; cardiovascular diseases; tumours; stem cell bioenergetics; ageing; carbohydrate, lipid, and protein metabolism.

Editor-in-Chief: Francesco Marincola, Sonata Therapeutics, USA

Franco Marincola is the Chief Scientific Officer of Sonata Therapeutics. Franco brings over 30 years of research and development experience in immunology, oncology and cell therapy to Sonata.

Most recently, Franco served as Senior Vice President and Global Head of Research at Kite Pharma where he led the research organization to identify novel therapies for hematologic malignancies and solid tumors. Prior to Kite, he was President and Chief Scientific Officer at Refuge Biotechnologies, where he developed research strategies for adoptive cell therapy products and led therapeutic programs based on nuclease deactivated CRISPR circuits. Prior to Refuge, Franco was Distinguished Research Fellow in Immune Oncology at AbbVie, and Chief Research Officer at Sidra Medical and Research Centre.

Before joining the biopharma industry, Franco spent more than two decades at the National Institutes of Health (NIH) and National Cancer Institute (NCI), most recently as a tenured senior investigator in cancer immunotherapy and biomarker research and as Chief Infectious Disease and Immunogenetics Investigator at the NIH Clinical Center.

Franco is the former President of the Society for Immunotherapy of Cancer (SITC). He currently serves as Editor-in-Chief for multiple peer-reviewed publications, including Journal of Translational Medicine, Translational Medicine Communications, and Immunotherapy, and is the author of more than 600 peer-reviewed publications.

Franco received his M.D. from the University of Milan and completed his residency at Stanford University.

Aims and scope

Journal of Translational Medicine is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.

The journal covers all areas of translational medicine but also has several special sections:

Annual Journal Metrics